Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

(2013) A. M. Aparicio et al.   CLINICAL CANCER RESEARCH

Re: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy

(2013) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Poor Survival in Prostate Cancer Patients with Primary Refractoriness to Docetaxel

(2013) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

New Perspectives in the Therapy of Castration Resistant Prostate Cancer

(2012) Pasquale Rescigno et al.   CURRENT DRUG TARGETS

Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer

(2012) Himisha Beltran et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

(2011) A. Flechon et al.   ANNALS OF ONCOLOGY

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

(2011) Carlo Buonerba et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Immunotherapy for the treatment of prostate cancer

(2011) Giuseppe Di Lorenzo et al.   Nature Reviews Clinical Oncology

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer

(2010) Giuseppe Di Lorenzo et al.   BJU INTERNATIONAL

Castration-Resistant Prostate Cancer

(2010) Giuseppe Di Lorenzo et al.   DRUGS

Docetaxel Rechallenge in Castration-Resistant Prostate Cancer: Scientific Legitimacy of Common Clinical Practice

(2010) Carlo Buonerba et al.   EUROPEAN UROLOGY

Sipuleucel-T for prostate cancer: the immunotherapy era has commenced

(2010) Carlo Buonerba et al.   Expert Review of Anticancer Therapy

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features

(2009) Y. Loriot et al.   ANNALS OF ONCOLOGY